1. Prognostication and Initiation of Therapy in Polycythemia Vera: Do We Have it Right?

   • Brady L Stein
   • Srdan Verstovsek

   Invited Commentary 14 October 2017 Pages: 507 - 509

2. Novel Pathways and Potential Therapeutic Strategies for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): CD123 and Beyond

   • Naveen Pemmaraju

   Invited Commentary 24 October 2017 Pages: 510 - 512

3. Models of Prognostication in Chronic Myelomonocytic Leukemia

   • Francesco Onida

   Myelodysplastic Syndromes (M Savona, Section Editor) 24 October 2017 Pages: 513 - 521

4. Genome-Editing Technologies in Adoptive T Cell Immunotherapy for Cancer

   • Nathan Singh
   • Junwei Shi
   • Marco Ruella

   CART and Immunotherapy (M Ruella, Section Editor) 16 October 2017 Pages: 522 - 529

5. Predicting Chemotherapy Resistance in AML

   • Cecilia C. S. Yeung
   • Jerald Radich

   Acute Myeloid Leukemias (H Erba, Section Editor) 10 April 2017 Pages: 530 - 536

   

6. Targeting IDH1 and IDH2 Mutations in Acute Myeloid Leukemia

   • Brittany Knick Ragon
   • Courtney D. DiNardo

   Acute Myeloid Leukemias (H Erba, Section Editor) 24 October 2017 Pages: 537 - 546

   

7. The Prognostic Significance of Measurable (“Minimal”) Residual Disease in Acute Myeloid Leukemia

   • Francesco Buccisano
   • Christopher S. Hourigan
   • Roland B. Walter

   Acute Myeloid Leukemias (H Erba, Section Editor) 13 October 2017 Pages: 547 - 556

8. Methods of Detection of Measurable Residual Disease in AML

   • Yi Zhou
   • Brent L. Wood

   Acute Myeloid Leukemias (H Erba, Section Editor) 02 November 2017 Pages: 557 - 567

   

9. Diagnostic and Prognostic Utility of Fluorescence In situ Hybridization (FISH) Analysis in Acute Myeloid Leukemia

   • Patrick R. Gonzales
   • Fady M. Mikhail

   Acute Myeloid Leukemias (H Erba, Section Editor) 24 October 2017 Pages: 568 - 573

   

10. Measurement of Residual Disease in Acute Myeloid Leukemia

    • Rahul S. Vedula
    • R. Coleman Lindsley

    Acute Myeloid Leukemias (H Erba, Section Editor) 24 October 2017 Pages: 574 - 581

    

11. Social Media in Hematology in 2017: Dystopia, Utopia, or Somewhere In-between?

    • Aaron T. Gerds
    • Teresa Chan

    Social Media Impact of Hematologic Malignancies (N Pemmaraju, Section Editor) 24 October 2017 Pages: 582 - 591

    

12. Analysis of First-Year Twitter Metrics of a Rare Disease Community for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) on Social Media: #BPDCN

    • Naveen Pemmaraju
    • Audun Utengen
    • Andrew A. Lane

    Social Media Impact of Hematologic Malignancies (N Pemmaraju, Section Editor) 24 October 2017 Pages: 592 - 597

    

13. Rare Cancers and Social Media: Analysis of Twitter Metrics in the First 2 Years of a Rare-Disease Community for Myeloproliferative Neoplasms on Social Media—#MPNSM

    • Naveen Pemmaraju
    • Audun Utengen
    • Michael A. Thompson

    Social Media Impact of Hematologic Malignancies (N Pemmaraju, Section Editor) 06 November 2017 Pages: 598 - 604

    

14. Using Social Media at National Meetings in Hematology—Optimal Use, Tips, Strategies, and Limitations

    • Aaron C. Logan

    Social Media Impact of Hematologic Malignancies (N Pemmaraju, Section Editor) 26 October 2017 Pages: 605 - 610

    

15. Novel Therapies for Myelofibrosis

    • Kristen Pettit
    • Olatoyosi Odenike

    Myeloproliferative Neoplasms (B Stein, Section Editor) 02 November 2017 Pages: 611 - 624